{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:59:17Z","timestamp":1790859557197,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The efficacy and safety of neurokinin-1 (NK-1) receptor antagonist in adults with cough remain unclear. Our objective was to systematically assess the efficacy and safety of NK-1 receptor antagonist for cough treatment using the latest available clinical evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A comprehensive literature retrieval was conducted across PubMed, Embase (via Ovid), the Cochrane Central Register of Controlled Trials (CENTRAL), and the\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      registry, encompassing data from database inception through 10 March 2026. This search aimed to identify randomized controlled trials (RCTs) assessing the therapeutic utility of NK-1 receptor antagonists in cough management. The abstracts and full-text articles were screened based on predefined inclusion and exclusion criteria. Meta-analysis was performed using R software (V 4.4.2). Main outcomes included the cough visual analog scale (VAS), awake objective cough frequency, urge to cough scale, 24-h cough frequency, and cough-specific patient-reported scale. Adverse events were also pooled.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five RCTs comprising a total 719 participants were included, evaluating three NK-1 receptor antagonists: aprepitant, orvepitant, and serlopitant. Compared to placebo, NK-1 receptor antagonists demonstrated significant antitussive efficacy by improving cough VAS scores (mean difference [MD] = \u22126.90, 95 CI (\u221210.90, \u22122.90), p &amp;lt; 0.0001) and cough-specific patient-reported scale (standardized mean difference [SMD] = 0.50, 95 CI (0.22, 0.78), p &amp;lt; 0.0001). Notably, the treatment group experienced a significant reduction in the urge to cough scale (SMD: \u22120.31, 95% CI (\u22120.40, - group (RR: 1.33, 95% CI (1.15, 1.53), p &amp;lt; 0.0001).No significant difference was detected at the overall effect estimates of objective cough frequency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NK-1 receptor antagonists provide modest improvements in patient-reported subjective cough outcomes, but show no statistically significant reduction in objective cough frequency. Given the small evidence base, clinical heterogeneity among pooled conditions, and higher incidence of mild adverse events, conclusions regarding their clinical benefit must be drawn with caution. Large-scale, high-quality clinical studies are required to confirm their efficacy and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1915023","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:31:47Z","timestamp":1790857907000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of neurokinin-1 receptor antagonist on cough suppression: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Ye","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, State Key Laboratory of Respiratory Health and Multimorbidity, Sichuan University, Laboratory of Pulmonary Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Clinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, State Key Laboratory of Respiratory Health and Multimorbidity, Sichuan University, Laboratory of Pulmonary Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101853","DOI":"10.1016\/j.pupt.2019.101853","article-title":"Emerging targets for cough therapies; NK1 receptor antagonists","volume":"59","author":"Badri","year":"2019","journal-title":"Pulm. Pharmacol. and Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"17534666241236025","DOI":"10.1177\/17534666241236025","article-title":"Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis","volume":"18","author":"Bali","year":"2024","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1007\/s00408-007-9034-x","article-title":"Quality of life and psychosocial aspects of cough","volume":"186","author":"Brignall","year":"2007","journal-title":"Lung"},{"key":"B4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1398-9995.2009.01973.x","article-title":"Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions","volume":"64","author":"Brozek","year":"2009","journal-title":"Allergy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/s0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet London, Engl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1378\/chest.14-1481","article-title":"Anatomy and neurophysiology of cough: CHEST Guideline and Expert Panel report","volume":"146","author":"Canning","year":"2014","journal-title":"Chest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00408-015-9701-2","article-title":"The impact of chronic cough: a cross-sectional European survey","volume":"193","author":"Chamberlain","year":"2015","journal-title":"Lung"},{"key":"B8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/9781119536604.ch10","article-title":"Analysing data and undertaking meta\u2010analyses","author":"Deeks","year":"2019","journal-title":"Cochrane Handbook Systematic Reviews Interventions"},{"key":"B9","doi-asserted-by":"publisher","first-page":"00012","DOI":"10.1183\/23120541.00012-2021","article-title":"Prevalence of stress urinary incontinence in women presenting for evaluation of chronic cough","volume":"7","author":"Dicpinigaitis","year":"2021","journal-title":"ERJ Open Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00408-019-00305-5","article-title":"The powerful placebo effect in cough: relevance to treatment and clinical trials","volume":"198","author":"Eccles","year":"2019","journal-title":"Lung"},{"key":"B11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1586\/ecp.12.20","article-title":"Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis","volume":"5","author":"Giuliano","year":"2012","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ Clin. Research ed."},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1503\/cmaj.060410","article-title":"The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey","volume":"176","author":"Ioannidis","year":"2007","journal-title":"CMAJ Can. Med. Assoc. J. = J. de l'Association medicale Can."},{"key":"B15","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ Clin. Res. ed."},{"key":"B16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jamainternmed.2020.5651","article-title":"Association of therapies with reduced pain and improved quality of life in patients with fibromyalgia: a systematic review and meta-analysis","volume":"181","author":"Mascarenhas","year":"2021","journal-title":"JAMA Internal Medicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/cpt.2003","article-title":"Mechanisms and rationale for targeted therapies in refractory and unexplained chronic cough","volume":"109","author":"Mazzone","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/9781119536604.ch12","article-title":"Synthesizing and presenting findings using other methods","author":"Mckenzie","year":"2019","journal-title":"Cochrane Handb. Syst. Rev. Interventions"},{"key":"B19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nrgastro.2011.272","article-title":"The risks of PPI therapy","volume":"9","author":"Moayyedi","year":"2012","journal-title":"Nat. Rev. Gastroenterology and Hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1007\/s00408-009-9185-z","article-title":"The cough hypersensitivity syndrome: a novel paradigm for understanding cough","volume":"188","author":"Morice","year":"2009","journal-title":"Lung"},{"key":"B21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1164\/rccm.200607-892OC","article-title":"Opiate therapy in chronic cough","volume":"175","author":"Morice","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01136-2019","article-title":"ERS guidelines on the diagnosis and treatment of chronic cough in adults and children","volume":"55","author":"Morice","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"878","DOI":"10.7326\/0003-4819-146-12-200706190-00009","article-title":"Ethical issues in stopping randomized trials early because of apparent benefit","volume":"146","author":"Mueller","year":"2007","journal-title":"Ann. Internal Medicine"},{"key":"B24","article-title":"A dose-ranging Study of orvepitant in patients with chronic refractory cough","year":"2022","journal-title":"Clin. Gov."},{"key":"B25","volume-title":"Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough","year":"2019"},{"key":"B26","volume-title":"Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF-COMFORT)","year":"2025"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.chest.2019.11.048","article-title":"Aprepitant for cough suppression in advanced lung cancer: a randomized trial","volume":"157","author":"Noronha","year":"2020","journal-title":"Chest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/S0140-6736(12)60776-4","article-title":"Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Ryan","year":"2012","journal-title":"Lancet London, Engl."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00408-023-00666-y","article-title":"The therapeutic landscape in chronic cough","volume":"202","author":"Smith","year":"2023","journal-title":"Lung"},{"key":"B30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.chest.2019.08.001","article-title":"The Neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot Study (VOLCANO-1)","volume":"157","author":"Smith","year":"2019","journal-title":"Chest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1164\/rccm.202006-2359OC","article-title":"Aprepitant for cough in lung cancer. A randomized placebo-controlled trial and mechanistic insights","volume":"203","author":"Smith","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1183\/09031936.00218714","article-title":"The global epidemiology of chronic cough in adults: a systematic review and meta-analysis","volume":"45","author":"Song","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1378\/chest.15-1271","article-title":"Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial","volume":"149","author":"Vertigan","year":"2016","journal-title":"Chest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00228-017-2245-z","article-title":"Tolerability of new antiepileptic drugs: a network meta-analysis","volume":"73","author":"Zaccara","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1816238","DOI":"10.3389\/fnins.2026.1816238","article-title":"Substance P-expressing neurons in the hypothalamic paraventricular nucleus mediate chronic cough hypersensitivity via the hypothalamus-airway neural pathway","volume":"20","author":"Zhang","year":"2026","journal-title":"Front. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1915023\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:31:48Z","timestamp":1790857908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1915023\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":35,"alternative-id":["10.3389\/fphar.2026.1915023"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1915023","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1915023"}}